Comparative Analysis of Compendial Quality Requirements for Carvedilol Products

INTRODUCTION. Carvedilol is a drug used to treat renovascular hypertension and cardiovascular diseases. A monograph for carvedilol drug substance has been included in the State Pharmacopeia of the Russian Federation (SP RF); however, quality requirements lack for carvedilol products. In order to develop a relevant monograph, it appears feasible to systematize current Russian and global compendial requirements for carvedilol products.

AIM. This study aimed to develop an approach to quality control of carvedilol medicinal products (tablets) and carvedilol drug substance.

DISCUSSION. According to Russian State register of medicines, carvedilol drug substance by seven manufacturers and 18 authorized products in the form of tablets (of them, 11 authorized in the EAEU) are marketed in the Russian Federation. Carvedilol drug substance is included in SP RF, ed. XV, as well as the leading world pharmacopeias — European Pharmacopoeia (Ph. Eur.), British Pharmacopoeia (ВР), US Pharmacopeia (USP), Indian Pharmacopoeia (IP), Chinese Pharmacopoeia (ChP), Japanese Pharmacopoeia (JP), and Korean Pharmacopoeia (КР). Monographs for carvedilol tablets were included in several leading pharmacopeias — ВР, USP, IP, ChP, JP; ChP included a monograph for carvedilol capsules. The requirements were compared for key quality parameters: Identification, Related impurities, and Assay for the substance and the tablets; and Dissolution (additionally) for tablets. Standardization approaches to impurities and Dissolution test differ significantly between the pharmacopeias; basic methods to control impurities typically include high-performance liquid chromatography (HPLC); infrared spectroscopy is the basic identification method.

CONCLUSIONS. A uniform approach has been suggested based on a comparative analysis of compendial documents. The approach helps to define quality requirements for carvedilol (drug substance and tablets): choosing high-priority parameters; providing a rationale for analytical methods (infrared spectroscopy, HPLC, titrimetry/HPLC assay, and dissolution); and setting standard requirements for risk-based control of impurities. The suggested approach is applicable for expert evaluation of carvedilol dossier and monograph draft for SP RF.

1. Talitsky KA, Bulkina OS, Karpov YuA. Beta-blockers in the treatment of arterial hypertension: past or future? Focus on carvedilol. RMJ. 2010;18(22):1343–7 (In Russ.). EDN: PRNPJZ

2. Liventseva MM. Beta blockers in cardiology. Role of carveland in treatment of basic cardiological diseases. Medical News. 2021;(11):47–9 (In Russ.). EDN: RTOODJ

3. Zarudii FS, Garifullin BN, Zakirova AN. Features of the structure and activity of carvedilol. Experimental and Clinical Pharmaco¬logy. 2010;73(1):40–3 (In Russ.). EDN: TNJZZD

4. Kartsova LA, Obedkova EV, Protasova ID. Enantioseparation of non-steroidal anti-inflammatory drugs and β-blockers by high-performance thin-layer chromatography. Sorption and Chromatography Processes. 2013;13(3):257–65 (In Russ.). EDN: QOXEBB

5. Sergeev BM, Mikhalev SP, Morozov YuN, et al. Cryomodification of drugs: micronized amorphous state of carvedilol. Moscow University Chemistry Bulletin. 2010;65(6):366–9. https://doi.org/10.3103/S0027131410060064. EDN: OGCKPR.

6. Popova MI, Kobeleva TA, Sichko AI. Spectrophotometric analysis of carvedilol in a medication based on aquacomplex of titanium glycerosolvate. Aspirantskiy Vestnik Povolzhiya. 2022;22(2):67–72 (In Russ.). https://doi.org/10.55531/2072-2354.2022.22.2.67-72

7. Popova MI. Main methods of quality control of bета-blocker drugs and application of spectrophotometry in the analysis of antiangiogenic ointments on tizol gel (Review). Problems of Biological, Medical and Pharmaceutical Chemistry. 2024;27(1):47–54 (In Russ.). https://doi.org/10.29296/25877313-2024-01-06

8. Zuev AP, Sadchikova NP, Tyulyaev II, et al. Development of the composition and production technology of carvedilol tablets. Pharm Chem J. 2003;37(11):594–8. https://doi.org/10.1023/B:PHAC.0000016071.91002.22. EDN: SVZPSR.

9. Onuchak LA, Vasileva MV, Kudashkina EV, Kuraeva JuG. Column and thin-layer liquid chromatography of antihypertensive drugs captopril, carvedilol, bisoprolol, atenolol, and amlodipine. Sorption and Chromatography Processes. 2012;12(3):355–62 (In Russ.). EDN: OZMANF

10. Popova MI, Kobeleva TA, Sichko AI. Review of the release kinetics of carvedilol and nebivolol from ointments for the treatment of hemangiomas. Problems of Modern Science and Education. 2022;(2):74–8 (In Russ.). EDN: KVLRFL